branded medications, which one they prefer and why. Free download On-demand Webinar ePrescribing and Active Ingredient Prescribing in MedicalDirector Helix and Clinical ePrescribing and Active Ingredient Prescribing are the latest in a long line of industry changes. Practitioners need to stay ...
Support for your practice Formulary tool See if RYBELSUS® is covered in your area. Check coverage Cost navigator tool Get an estimate of your patient’s cost. Check costs Prescribing Information Read important information about RYBELSUS®. Download the PI Support for your patients ...
The Recovery Village aims to improve the quality of life for people struggling with a substance use or mental health disorder with fact-based content about the nature of behavioral health conditions, treatment options and their related outcomes. We publish material that is researched, cited, edited...
The first and onlynon-stimulantfor ADHD in a liquid formulation. Learn More and Access Savings! Please see Important Safety Information,Full Prescribing InformationandPatient Information, including Instructions for Use. ONYDA is a trademark of Tris Pharma, Inc. ...
Please see Full Prescribing Information for Gadavist® (Imaging Bulk Package). ADDITIONAL IMPORTANT SAFETY INFORMATION FOR EOVIST® Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of Eovist®. Extravasation into tissues during Eovist® administration...
A website tailored to New York State healthcare professionals with extensive resources to use for helping tobacco-using patients quit. Includes treating nicotine addiction, prescribing cessation medications, and other helpful links. Show Toolkits & E-Learning A variety of tobacco cessation toolkits ...
Physical Therapist Case Study: Achilles tendon reinjury due to improperly prescribing a stretching exercise Physical Therapist Case Study: Alleged improper management over the course of treatment following total hip arthroplasty Physical Therapist Case Study: Failure to appropriately monitor a patient wit...
Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose. Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. ...
Please see the RituxanPrescribing InformationandMedication Guideincluding Most Serious Side Effects for additional Important Side Effect Information.
Pleaseclick herefor Saxenda®Prescribing Information, including Boxed Warning. Important Safety Information for Wegovy® WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is un...